The article offers a look at the efforts to search for new treatments of triple-negative breast cancer (TNBC). TNBC is considered as the most difficult type of breast cancer to treat. It is characterized as an extremely aggressive cancer with limited treatment options. Oncologists and ...
Researchers discover new treatment target for triple-negative breast cancer byUniversity of Kentucky Proposed model. High expression of NAC1 in TNBC promotes tumor stemness and induces secretion of immunosuppressive cytokines, which orchestrate tumor infiltration of MDSCs and NK cells and tumor stemness....
The new treatment protocol — which has been dubbed CamRelief — achieved this without producing any uncontrollable adverse effects, the researchers said. The CamRelief study involved 441 Chinese women aged 18 to 75 with early-stage or locally advanced TNBC. Notably, it included a higher proportion...
"We knew that ACSS2 was a promising target for TNBC. Our research shows us how the immune effects of ACSS2 inhibition could eventually be used in for TNBC patients with limited treatment options," said Schug. "More research is needed, but by combining this approach with othercancertherapies,...
The US Food and Drug Administration (FDA) granted accelerated approval tosacituzumab govitecan(Trodelvy, Immunomedics) for the treatment of metastatic triple-negativebreast cancer(TNBC). Eligible patients must have received at least two prior therapies. ...
The limited treatment options for recurrent TNBC have traditionally been cytotoxic chemotherapeutic agents due to the absence of molecular targets expressed in more common types of breast malignancies. There is ongoing exploration of adjuvant immunotherapy for TNBC, with various categories of approaches bein...
NICE said that around 650 people with advanced TNBC are now eligible for treatment with Trodelvy, a first-in-class intravenously administered drug that targets TROP-2 on breast cancer cells. It already recommends use of Roche's PD-L1 inhibitor Tecentriq (atezolizumab) with chemotherapy for TNBC,...
Triple-negative breast cancer (TNBC) is a challenging subtype compared with its counterparts. Despite improved accuracy, treatment options remain limited compared with other subtypes of breast cancer. Findings from the KEYNOTE-522 trial (NCT03036488) demonstrated a significant incre...
Surgery is the traditional treatment for cancer and is the most effective way to eliminate multiple cancers before they develop lymph node or distant metastasis [3]. Radiation therapy preferentially kills rapidly dividing cells and cells that are difficult to repair their own DNA, and cancer cells ...
Pyroptosis, a highly immunogenic type of cell death, initiates local inflammation and attracts inflammatory cells for infiltration. This offers an opportunity to alleviate the immune suppression within the tumor microenvironment (TME) and stimulate systemic immune responses during the treatment of solid ...